1
|
Thurin NH, Jové J, Lassalle R, Rouyer M, Lamarque S, Bosco-Levy P, Segalas C, Schneeweiss S, Blin P, Droz-Perroteau C. Strong instrumental variables biased propensity scores in comparative effectiveness research: A case study in oncology. J Clin Epidemiol 2023; 155:31-38. [PMID: 36657590 DOI: 10.1016/j.jclinepi.2023.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 12/10/2022] [Accepted: 01/11/2023] [Indexed: 01/18/2023]
Abstract
BACKGROUND AND OBJECTIVES Some medications require specific medical procedures in the weeks before their start. Such procedures may meet the definition of instrumental variables (IVs). We examined how they may influence treatment effect estimation in propensity score (PS)-adjusted comparative studies, and how to remedy. STUDY DESIGN AND SETTING Different covariate assessment periods (CAPs) did and did not include the month preceding treatment start were used to compute PS in the French claims database (Sytème National des Données de Santé-SNDS), and 1:1 match patients with metastatic castration resistant prostate cancer initiating abiraterone acetate or docetaxel. The 36-month survival was assessed. RESULTS Among 1, 213 docetaxel and 2, 442 abiraterone initiators, the PS distribution resulting from the CAP [-12; 0 months] distinctly separated populations (c = 0.93; 273 matched pairs). The CAPs [-12;-1 months] identified 765 pairs (c = 0.81). Strong docetaxel treatment predictors during the month before treatment start were implantable delivery systems (1% vs. 59%), which fulfilled IV conditions. The 36-month survival was not meaningfully different under the [-12; 0 months] CAP but differed by 10% points (38% vs. 28%) after excluding month -1. CONCLUSION In the setting of highly predictive pretreatment procedures, excluding the immediate pre-exposure time from the CAP will reduce the risk of including potential IVs in PS models and may reduce bias.
Collapse
Affiliation(s)
- Nicolas H Thurin
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France.
| | - Jérémy Jové
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Régis Lassalle
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Magali Rouyer
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Stéphanie Lamarque
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Pauline Bosco-Levy
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Corentin Segalas
- University of Paris Cité, Centre of Epidemiology and Statistics (CRESS) INSERM, Paris, France
| | - Sebastian Schneeweiss
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Patrick Blin
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | | |
Collapse
|
2
|
Thurin NH, Rouyer M, Jové J, Gross-Goupil M, Haaser T, Rébillard X, Soulié M, de Pouvourville G, Capone C, Bazil ML, Messaoudi F, Lamarque S, Bignon E, Droz-Perroteau C, Moore N, Blin P. Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French Nationwide Claims Database. Expert Rev Clin Pharmacol 2022; 15:1139-1145. [PMID: 35984212 DOI: 10.1080/17512433.2022.2115356] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES To conduct the direct comparison of abiraterone acetate and docetaxel for first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-life settings. METHODS Data were extracted from the French nationwide claims database (SNDS) on all men aged ≥40 years starting first-line treatment with abiraterone acetate or docetaxel for mCRPC in 2014. A high-dimensional propensity score including 100 baseline characteristics was used to match patients of both groups and form two comparative cohorts. Three-year overall survival and treatment discontinuation-free survival were determined using Kaplan-Meier analysis. RESULTS In 2014, 2,444 patients started abiraterone for treatment of mCRPC and 1,214 started docetaxel. After trimming and matching, 716 patients were available in each group. Median overall survival tended to be longer in the abiraterone acetate cohort (23.8 months, 95% confidence interval = [21.5; 26.0]) than in the docetaxel cohort (20.3 [18.4; 21.6] months). Survival at 36 months was 34.6% for abiraterone acetate and 27.9% for docetaxel (p = 0.0027). Treatment discontinuation-free median was longer in the abiraterone acetate cohort compared to the docetaxel cohort (10.8 [10.1; 11.7] versus 7.4 [7.0; 8.0] months). CONCLUSION The findings underline the interest of oral abiraterone acetate over intravenous docetaxel as the first-line treatment option in mCRPC.
Collapse
Affiliation(s)
- Nicolas H Thurin
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Magali Rouyer
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Jérémy Jové
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Marine Gross-Goupil
- Medical Oncology Department, Hôpital Saint-André, Bordeaux University Hospital, Bordeaux, France
| | - Thibaud Haaser
- Radiotherapy Department, Hôpital Haut Lévêque, Bordeaux University Hospital, Pessac, France
| | | | - Michel Soulié
- Urology Department, Hôpital Rangueil, Toulouse University Hospital, Toulouse, France
| | | | | | | | | | - Stéphanie Lamarque
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Emmanuelle Bignon
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | | | - Nicholas Moore
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| | - Patrick Blin
- University of Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, Bordeaux, France
| |
Collapse
|
3
|
Thurin N, Rouyer M, Gross-Goupil M, Haaser T, Rébillard X, Soulié M, de Pouvourville G, Messaoudi F, Stitou El Amine Demnati H, Bignon E, Jové J, Lamarque S, Droz-Perroteau C, Moore N, Blin P. Impact de la séquence première-deuxième ligne de traitement, acétate d’abiraterone-docétaxel versus docétaxel-acétate d’abiratérone, sur la survie dans le cancer de la prostate résistant à la castration et métastatique ; Étude de cohorte dans le SNDS. Rev Epidemiol Sante Publique 2021. [DOI: 10.1016/j.respe.2021.05.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
4
|
Thurin NH, Bosco-Levy P, Blin P, Rouyer M, Jové J, Lamarque S, Lignot S, Lassalle R, Abouelfath A, Bignon E, Diez P, Gross-Goupil M, Soulié M, Roumiguié M, Le Moulec S, Debouverie M, Brochet B, Guillemin F, Louapre C, Maillart E, Heinzlef O, Moore N, Droz-Perroteau C. Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data. BMC Med Res Methodol 2021; 21:95. [PMID: 33933001 PMCID: PMC8088022 DOI: 10.1186/s12874-021-01285-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Accepted: 04/15/2021] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND Diagnosis performances of case-identifying algorithms developed in healthcare database are usually assessed by comparing identified cases with an external data source. When this is not feasible, intra-database validation can present an appropriate alternative. OBJECTIVES To illustrate through two practical examples how to perform intra-database validations of case-identifying algorithms using reconstituted Electronic Health Records (rEHRs). METHODS Patients with 1) multiple sclerosis (MS) relapses and 2) metastatic castration-resistant prostate cancer (mCRPC) were identified in the French nationwide healthcare database (SNDS) using two case-identifying algorithms. A validation study was then conducted to estimate diagnostic performances of these algorithms through the calculation of their positive predictive value (PPV) and negative predictive value (NPV). To that end, anonymized rEHRs were generated based on the overall information captured in the SNDS over time (e.g. procedure, hospital stays, drug dispensing, medical visits) for a random selection of patients identified as cases or non-cases according to the predefined algorithms. For each disease, an independent validation committee reviewed the rEHRs of 100 cases and 100 non-cases in order to adjudicate on the status of the selected patients (true case/ true non-case), blinded with respect to the result of the corresponding algorithm. RESULTS Algorithm for relapses identification in MS showed a 95% PPV and 100% NPV. Algorithm for mCRPC identification showed a 97% PPV and 99% NPV. CONCLUSION The use of rEHRs to conduct an intra-database validation appears to be a valuable tool to estimate the performances of a case-identifying algorithm and assess its validity, in the absence of alternative.
Collapse
Affiliation(s)
- Nicolas H. Thurin
- INSERM CIC-P1401, Bordeaux PharmacoEpi, Univ. Bordeaux, Bordeaux, France
| | - Pauline Bosco-Levy
- INSERM CIC-P1401, Bordeaux PharmacoEpi, Univ. Bordeaux, Bordeaux, France
| | - Patrick Blin
- INSERM CIC-P1401, Bordeaux PharmacoEpi, Univ. Bordeaux, Bordeaux, France
| | - Magali Rouyer
- INSERM CIC-P1401, Bordeaux PharmacoEpi, Univ. Bordeaux, Bordeaux, France
| | - Jérémy Jové
- INSERM CIC-P1401, Bordeaux PharmacoEpi, Univ. Bordeaux, Bordeaux, France
| | - Stéphanie Lamarque
- INSERM CIC-P1401, Bordeaux PharmacoEpi, Univ. Bordeaux, Bordeaux, France
| | - Séverine Lignot
- INSERM CIC-P1401, Bordeaux PharmacoEpi, Univ. Bordeaux, Bordeaux, France
| | - Régis Lassalle
- INSERM CIC-P1401, Bordeaux PharmacoEpi, Univ. Bordeaux, Bordeaux, France
| | | | - Emmanuelle Bignon
- INSERM CIC-P1401, Bordeaux PharmacoEpi, Univ. Bordeaux, Bordeaux, France
| | - Pauline Diez
- INSERM CIC-P1401, Bordeaux PharmacoEpi, Univ. Bordeaux, Bordeaux, France
| | - Marine Gross-Goupil
- Department of Medical Oncology, Hôpital Saint André, CHU de Bordeaux, Bordeaux, France
| | - Michel Soulié
- Department of Urology, University Hospital of Rangueil, CHU de Toulouse, Toulouse, France
| | - Mathieu Roumiguié
- Department of Urology, University Hospital of Rangueil, CHU de Toulouse, Toulouse, France
| | | | - Marc Debouverie
- Department of Neurology, CHRU de Nancy, Nancy, France
- Université de Lorraine, EA 4360 APEMAC, Nancy, France
| | - Bruno Brochet
- CRC SEP, Neurology Department, CHU de Bordeaux, Bordeaux, France
- INSERM U1215, Neurocentre Magendie, Univ. Bordeaux, Bordeaux, France
| | - Francis Guillemin
- Université de Lorraine, EA 4360 APEMAC, Nancy, France
- INSERM CIC 1433 Epidémiologie Clinique, CHRU de Nancy, Nancy, France
| | - Céline Louapre
- Sorbonne Université, Institut du cerveau, ICM, Hôpital de la Pitié Salpêtrière, INSERM UMR S 1127, CNRS UMR 7225, Paris, France
- Neurology Department, Hôpital de la Pitié Salpêtrière, APHP, Paris, France
| | - Elisabeth Maillart
- Neurology Department, Hôpital de la Pitié Salpêtrière, APHP, Paris, France
| | - Olivier Heinzlef
- Department of Neurology, Hôpital CHI de Poissy/Saint-Germain-en-Laye, Paris, France
| | - Nicholas Moore
- INSERM CIC-P1401, Bordeaux PharmacoEpi, Univ. Bordeaux, Bordeaux, France
| | | |
Collapse
|
5
|
Gross-Goupil M, Thurin NH, Rouyer M, Haaser T, Rebillard X, Soulie M, de Pouvourville G, Messaoudi F, Capone C, Bignon E, Jové J, Lamarque S, Droz-Perroteau C, Moore N, Blin P. Impact of treatment sequence on survival outcome in patients with a second treatment line for metastatic castration-resistant prostate cancer: A new user design in the French nationwide claims database. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.6_suppl.91] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
91 Background: Abiraterone acetate in association with prednisone/prednisolone and docetaxel can both be used as first or second line treatments for metastatic castration-resistant prostate cancer (mCRPC). As a result, one may wonder if it is better to start with an abiraterone acetate first line followed by a docetaxel second line (ABI–DOCE sequence) or to use the inverse sequence DOCE-ABI. Methods: A new user cohort study design with a 3-year follow-up: patients initiating a first-line treatment for mCRPC in 2014 followed by a second treatment line were identified from the French nationwide claims database (SNDS), which covers about 86% of the population at the time of the study. Patients with sequence ABI–DOCE and those with DOCE-ABI were 1:1 matched on prostate cancer stage before mCRPC status, duration from prostate cancer diagnosis, and a high-dimensional propensity score. The 36-month overall survival and the 36-month survival time until treatment switch or death (proxy of progression-free survival) were compared using Cox proportional hazards risk model. Results: Out of the 3 949 mCRPC patients that initiated a first-line treatment in 2014, 1 162 died during this first line, and 2 283 had a second-line treatment. Among them, 693 received the sequence ABI–DOCE and 354 DOCE–ABI. A total of 159 patients per group were 1:1 matched. The median duration of the first treatment line was 8.4 months in the ABI–DOCE sequence and 6.6 months in the DOCE–ABI sequence. The median duration of the second line was 6.3 months and 6.5 months in the ABI–DOCE and DOCE–ABI sequences, respectively. Results are presented in the table below. Median survivals were similar in both groups with no significant differences observed in the 36-month survival probabilities. Around 60% of the patients received a third-line treatment in both groups. Conclusions: In real life settings, treatment sequences (ABI–DOCE versus DOCE–ABI) seem to have no differential impact on survival outcome in mCRPC patients sharing same characteristics. [Table: see text]
Collapse
Affiliation(s)
- Marine Gross-Goupil
- Centre Hospitalier Universitaire de Bordeaux-Hôpital Saint-André, Bordeaux, France
| | - Nicolas H. Thurin
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, Bordeaux, France
| | - Magali Rouyer
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, Bordeaux, France
| | | | | | - Michel Soulie
- Centre Hospitalier Universitaire Rangueil, Toulouse, France
| | | | | | | | - Emmanuelle Bignon
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, Bordeaux, France
| | - Jérémy Jové
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, Bordeaux, France
| | | | | | - Nicholas Moore
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, CHU Bordeaux, Bordeaux, France
| | - Patrick Blin
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, Bordeaux, France
| |
Collapse
|
6
|
Thurin NH, Rouyer M, Gross-Goupil M, Rebillard X, Soulié M, Haaser T, Roumiguié M, Le Moulec S, Capone C, Pierrès M, Lamarque S, Jové J, Bignon E, Droz-Perroteau C, Moore N, Blin P. Epidemiology of metastatic castration-resistant prostate cancer: A first estimate of incidence and prevalence using the French nationwide healthcare database. Cancer Epidemiol 2020; 69:101833. [PMID: 33068878 DOI: 10.1016/j.canep.2020.101833] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 09/07/2020] [Accepted: 09/25/2020] [Indexed: 12/31/2022]
Abstract
BACKGROUND There is a lack of information about the burden of metastatic castration-resistant prostate cancer (mCRPC). The present work aims to estimate the incidence and prevalence of mCRPC in 2014 using the French nationwide healthcare database (SNDS). METHODS Prevalence and incidence were estimated based on an SNDS extraction of men covered by the general healthcare insurance (86 % of the French population), and aged ≥40. Patients with mCRPC were identified amongst prostate cancer cases using an algorithm estimating a date of first metastasis management and a date of castration resistance. This algorithm was validated by clinical experts through a blind review of 200 anonymized medical charts from SNDS data. Prevalence and incidence were standardized on the European Standard Population (2013 edition). RESULTS Prevalence and incidence of mCRPC were estimated as, respectively, 62 and 21 cases per 100 000 men in 2014. Less than one mCRPC case per 100 000 was observed in men aged 40-49. Maximum mCRPC incidence was in men aged 80-89 (175 per 100 000). The algorithm used for mCRPC identification had 97 % positive and 99 % negative predictive values. CONCLUSION The good performances of the algorithm for mCRPC identification and the consistency of the generated results with the existing data highlight the robustness of these first estimates of mCRPC prevalence and incidence. Future updates will call for algorithm adjustment as practices evolve over time. These first real-life data will serve for future follow-up of the impact of changes in the management of prostate cancer.
Collapse
Affiliation(s)
- Nicolas H Thurin
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, 33076, Bordeaux, France.
| | - Magali Rouyer
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, 33076, Bordeaux, France
| | - Marine Gross-Goupil
- Department of Medical Oncology, Hôpital Saint André, CHU de Bordeaux, 1 rue Jean Burguet, 33075, Bordeaux, France
| | - Xavier Rebillard
- Department of Urology, Clinique Beau Soleil, 119 Avenue de Lodeve, 34070, Montpellier, France
| | - Michel Soulié
- Department of Urology, University Hospital of Rangueil, CHU de Toulouse, 9 Place Lange, 31059, Toulouse, France
| | - Thibaud Haaser
- Department of Radiotherapy, Hôpital Haut-Lévêque, CHU de Bordeaux, Avenue Magellan, 33600, Pessac, France
| | - Mathieu Roumiguié
- Department of Urology, University Hospital of Rangueil, CHU de Toulouse, 9 Place Lange, 31059, Toulouse, France
| | - Sylvestre Le Moulec
- Department of Oncology, Clinique Marzet, 40 Boulevard d'Alsace, 64000, Pau, France
| | - Camille Capone
- Janssen, 1 rue Camille Desmoulins, 92130, Issy-les-Moulineaux, France
| | - Marie Pierrès
- Janssen, 1 rue Camille Desmoulins, 92130, Issy-les-Moulineaux, France
| | - Stéphanie Lamarque
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, 33076, Bordeaux, France
| | - Jérémy Jové
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, 33076, Bordeaux, France
| | - Emmanuelle Bignon
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, 33076, Bordeaux, France
| | - Cécile Droz-Perroteau
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, 33076, Bordeaux, France
| | - Nicholas Moore
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, 33076, Bordeaux, France
| | - Patrick Blin
- Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, 33076, Bordeaux, France
| |
Collapse
|
7
|
Thurin N, Rouyer M, Jové J, Gross-Goupil M, Haaser T, Rebillard X, Soulié M, De Pouvourville G, Capone C, Pierres M, Lamarque S, Bignon E, Droz-Perroteau C, Moore N, Blin P. Changes in therapeutic strategy in metastatic castration resistant prostate cancer (mCRPC) between 2012 and 2014 from the French nationwide claims database (SNDS). EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33183-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
8
|
Gross-Goupil M, Thurin NH, Rouyer M, Jové J, Haaser T, Rebillard X, Soulie M, de Pouvourville G, Pierrès M, Capone C, Lamarque S, Bignon E, Droz-Perroteau C, Moore N, Blin P. Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.5570] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5570 Background: Therapeutic strategy in metastatic castration-resistant prostate cancer (mCRPC) has evolved significantly with the introduction of abiraterone acetate in association with prednisone/prednisolone in first-line treatment in December 2012. This work aimed to compare the effectiveness of abiraterone acetate and docetaxel as first-line treatments for mCRPC, in real-life setting. Methods: Patients with mCRPC were identified in the main scheme of the National Healthcare System database (SNDS), which covers about 86% of the French population, and capturing all reimbursed healthcare expenditures and hospital discharge summaries. Those initiating docetaxel or abiraterone acetate in 1st line in 2014 were included and 1:1 matched on the previous prostate cancer stage before mCRPC status, the delay from the date of initial diagnosis and a high-dimensional propensity score. The 36-month overall survival and the 36-month discontinuation-free survival (i.e. survival time until treatment switch or death) were compared using Cox proportional hazards risk model. Results: In 2014, out of the 12,951 patients with prevalent mCRPC, 1,214 initiated docetaxel in 1st line and 2 444 initiated abiraterone. A total of 716 patients per group were matched with good comparability (C-statistic = 0.6). The median duration of docetaxel–defined as the time between the first and the last infusion–was 7.3 months with a median of 6 infusions. The median duration of abiraterone acetate–corresponding to the period covered by the dispensed drug–was 9.1 months. Near 70% of the docetaxel and 62% of the abiraterone acetate patients received a 2nd line of treatment. Results related to the main survival outcomes are presented in the table below. Conclusions: First-line treatment with abiraterone acetate in mCRPC patients results in a better 36-month overall survival and discontinuation-free survival compared to docetaxel in real-life setting. [Table: see text]
Collapse
Affiliation(s)
| | - Nicolas H. Thurin
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, Bordeaux, France
| | - Magali Rouyer
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, Bordeaux, France
| | - Jérémy Jové
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, Bordeaux, France
| | | | | | - Michel Soulie
- Centre Hospitalier Universitaire Rangueil, Toulouse, France
| | | | | | | | | | - Emmanuelle Bignon
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, Bordeaux, France
| | | | - Nicholas Moore
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, CHU Bordeaux, Bordeaux, France
| | - Patrick Blin
- Bordeaux PharmacoEpi, INSERM CIC1401, Univ. Bordeaux, Bordeaux, France
| |
Collapse
|
9
|
Ferreira A, Lamarque S, Boyer P, Perez-Diaz F, Jouvent R, Cohen-Salmon C. Spontaneous appetence for wheel-running: a model of dependency on physical activity in rat. Eur Psychiatry 2020; 21:580-8. [PMID: 17161285 DOI: 10.1016/j.eurpsy.2005.02.003] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2004] [Revised: 10/11/2004] [Accepted: 02/01/2005] [Indexed: 11/25/2022] Open
Abstract
AbstractAccording to human observations of a syndrome of physical activity dependence and its consequences, we tried to examine if running activity in a free activity paradigm, where rats had a free access to activity wheel, may present a valuable animal model for physical activity dependence and most generally to behavioral dependence. The pertinence of reactivity to novelty, a well-known pharmacological dependence predictor was also tested. Given the close linkage observed in human between physical activity and drugs use and abuse, the influence of free activity in activity wheels on reactivity to amphetamine injection and reactivity to novelty were also assessed. It appeared that (1) free access to wheel may be used as a valuable model for physical activity addiction, (2) two populations differing in activity amount also differed in dependence to wheel-running. (3) Reactivity to novelty did not appeared as a predictive factor for physical activity dependence (4) activity modified novelty reactivity and (5) subjects who exhibited a high appetence to wheel-running, presented a strong reactivity to amphetamine. These results propose a model of dependency on physical activity without any pharmacological intervention, and demonstrate the existence of individual differences in the development of this addiction. In addition, these data highlight the development of a likely vulnerability to pharmacological addiction after intense and sustained physical activity, as also described in man. This model could therefore prove pertinent for studying behavioral dependencies and the underlying neurobiological mechanisms. These results may influence the way psychiatrists view behavioral dependencies and phenomena such as doping in sport or addiction to sport itself.
Collapse
|
10
|
Rouyer M, Oudard S, Joly F, Fizazi K, Tubach F, Jove J, Lacueille C, Lamarque S, Guiard E, Balestra A, Droz-Perroteau C, Fourrier-Reglat A, Moore N. Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. Br J Cancer 2019; 121:1001-1008. [PMID: 31719685 PMCID: PMC6964680 DOI: 10.1038/s41416-019-0611-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Revised: 09/24/2019] [Accepted: 10/10/2019] [Indexed: 01/25/2023] Open
Abstract
Background Cabazitaxel is a treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure. The FUJI cohort aimed to confirm the real-life overall and progression-free survival (OS, PFS) and safety of cabazitaxel. Methods Multicentre, non-interventional cohort of French mCRPC patients initiating cabazitaxel between 2013 and 2015, followed 18 months. Results Four hundred one patients were recruited in 42 centres. At inclusion, median age was 70, main metastatic sites were bones (87%), lymph nodes (42%) and visceral (20%). 18% had cabazitaxel in 2nd-line treatment, 39% in 3rd-line and 43% in 4th-line or beyond. All had prior docetaxel, and 82% prior abiraterone, enzalutamide or both. Median duration of cabazitaxel treatment was 3.4 months. Median OS from cabazitaxel initiation was 11.9 months [95% CI: 10.1–12.9]. In multivariate analyses, grade ≥ 3 adverse events, visceral metastases, polymedication, and >5 bone metastases were associated with a shorter OS. Main grade ≥ 3 adverse events were haematological with 8% febrile neutropenia. Conclusion Real-life survival with cabazitaxel in FUJI was shorter than in TROPIC (pivotal trial, median OS 15.1 months) or PROSELICA (clinical trial 20 vs 25 mg/m2, median OS, respectively, 13.4 and 14.5 months). There was no effect of treatment-line on survival. No unexpected adverse concerns were identified. Study registration It was registered with the European Medicines Agency EUPASS registry, available at www.encepp.eu, as EUPAS10391. It has been approved as an ENCEPP SEAL study.
Collapse
Affiliation(s)
- Magali Rouyer
- Bordeaux PharmacoEpi, CIC1401, University of Bordeaux, Bordeaux, France
| | - Stéphane Oudard
- Medical Oncology Department, Hôpital Européen Georges Pompidou, Université Paris Descartes, Paris, France
| | - Florence Joly
- Medical Oncology Department, Centre François Baclesse, CHU Côte de Nacre, Caen, France
| | - Karim Fizazi
- Medical Oncology Department, Institut Gustave Roussy, Villejuif, France
| | - Florence Tubach
- Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, Unité de Recherche Clinique PSL-CFX, Centre de Pharmacoépidémiologie (Cephepi), Inserm, UMR 1123 ECEVE, CIC-1421, Paris, France
| | - Jérémy Jove
- Bordeaux PharmacoEpi, CIC1401, University of Bordeaux, Bordeaux, France
| | | | | | - Estelle Guiard
- Bordeaux PharmacoEpi, CIC1401, University of Bordeaux, Bordeaux, France
| | - Aurélie Balestra
- Bordeaux PharmacoEpi, CIC1401, University of Bordeaux, Bordeaux, France
| | | | - Annie Fourrier-Reglat
- Bordeaux PharmacoEpi, CIC1401, University of Bordeaux, Bordeaux, France.,Inserm U1219, Bordeaux, France
| | - Nicholas Moore
- Bordeaux PharmacoEpi, CIC1401, University of Bordeaux, Bordeaux, France. .,Inserm U1219, Bordeaux, France.
| | | |
Collapse
|
11
|
Thurin N, Rouyer M, Gross-Goupil M, Rebillard X, Soulié M, Haaser T, De Pouvourville G, Pierrès M, Chevalier J, Lamarque S, Jové J, Bignon E, Droz-Perroteau C, Moore N, Blin P. Épidémiologie du cancer de la prostate résistant à la castration et métastatique : données françaises à partir du SNDS. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Thurin N, Rouyer M, Gross-Goupil M, Soulié M, Roumiguié M, Le Moulec S, Capone C, Chevalier J, Lamarque S, Bignon E, Jové J, Droz-Perroteau C, Moore N, Blin P. Validation d’un algorithme complexe dans le Système national des données de santé. Exemple avec le cancer de la prostate résistant à la castration et métastatique. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.04.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
13
|
Blin P, Samama CM, Sautet A, Benichou J, Lignot-Maleyran S, Lamarque S, Lorrain S, Lassalle R, Droz-Perroteau C, Mismetti P, Moore N. Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study. Pharmacol Res 2018; 141:201-207. [PMID: 30583081 DOI: 10.1016/j.phrs.2018.12.018] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Revised: 12/19/2018] [Accepted: 12/20/2018] [Indexed: 12/01/2022]
Abstract
BACKGROUND Venous thromboembolism (VTE) after total knee or hip replacement (TKR, THR) is usually prevented with low-molecular weight heparin (LMWH), and increasingly by direct oral anticoagulants (DOAC). The aim of the present study was to compare the benefit-risk and medical costs of DOAC vs. LMWH in a real-life setting. METHODS All patients with THR or TKR in France between Jan-1st 2013 and Sep-30th 2014, discharged to home, were identified and followed-up for 3 months in the French nationwide claims database, SNDS. DOAC users were 1:1 matched with LWMH users on gender, age and propensity score. Relative risks (RR) of hospitalized VTE, hospitalized bleeding and death were estimated using quasi-Poisson models. Medical costs were calculated according to the societal perspective, including total cost for outpatient claims and national DRG costs for hospitalisations. RESULTS Most DOAC users (≥ 98.8%) were matched to a LMWH patient. For the 63,238 matched THR patients, the 3-month absolute risk of VTE was 0.9‰ with DOAC and 2.5‰ with LMWH (RR = 0.35 [0.23 to 0.54]), of bleeding 1.8‰ and 2.1‰ (0.88 [0.62-1.25]), death 0.7‰ and 1.1‰ (0.68 [0.40-1.15]). For the 31,440 matched TKR patients, risks were 1.6‰ and 2.3‰ (0.69 [0.42-1.16]) for VTE, 2.4‰ and 3.8‰ (0.64 [0.43 to 0.97]) for bleeding, and 0.6‰ and 0.8‰ (0.69 [0.30-1.62]) for all-cause death. Mean medical costs were 28% and 21% lower with DOAC than LMWH for THR and TKR, respectively. This nationwide study found a very low risk of VTE, hospitalized bleeding and death after THR or TKR discharge in patients with VTE prevention in real-life setting, with better benefit-risk profiles of DOAC compared to LMWH, and associated cost savings.
Collapse
Affiliation(s)
- Patrick Blin
- Bordeaux Pharmacoepi, Inserm CIC1401, Bordeaux University, 33076, Bordeaux, France.
| | - Charles-Marc Samama
- Cochin University Hospital, Paris Descartes University, Paris, 75014, France
| | - Alain Sautet
- Saint-Antoine University Hospital, Paris, 75010, France
| | | | | | - Stéphanie Lamarque
- Bordeaux Pharmacoepi, Inserm CIC1401, Bordeaux University, 33076, Bordeaux, France
| | - Simon Lorrain
- Bordeaux Pharmacoepi, Inserm CIC1401, Bordeaux University, 33076, Bordeaux, France
| | - Régis Lassalle
- Bordeaux Pharmacoepi, Inserm CIC1401, Bordeaux University, 33076, Bordeaux, France
| | | | | | - Nicholas Moore
- Bordeaux Pharmacoepi, Inserm CIC1401, Bordeaux University, 33076, Bordeaux, France; INSERM U1219, Bordeaux, 33076, France
| |
Collapse
|
14
|
Oudard S, Fizazi K, Joly F, Tubach F, Rouyer M, Lamarque S, Guiard E, Balestra A, Lacueille C, Jové J, Droz-Perroteau C, Fourrier-Réglat A, Moore N. Cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC): Real-life use, effectiveness, safety, and quality of life (QoL) in the FUJI cohort. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.5025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Florence Joly
- Centre François Baclesse, CHU Côte de Nacre, Univ. UniCaen, Caen, France
| | - Florence Tubach
- Centre de Pharmacoépidémiologie (Céphépi), Sorbonne Univ., Faculté de médecine Sorbonne Univ., AP-HP, Hôpital Pitié-Salpêtrière, INSERM, UMR 1123, CIC-P 1421, Paris, France
| | - Magali Rouyer
- Bordeaux PharmacoEpi, Univ Bordeaux, Inserm CIC1401, Bordeaux, France
| | | | - Estelle Guiard
- Bordeaux PharmacoEpi, CIC1401, Univ. Bordeaux, Bordeaux, France
| | | | | | - Jérémy Jové
- Bordeaux PharmacoEpi, CIC1401, Univ. Bordeaux, Bordeaux, France
| | | | - Annie Fourrier-Réglat
- Bordeaux PharmacoEpi, Univ. Bordeaux, Inserm CIC1401 & U1219, CHU Bordeaux, Bordeaux, France
| | - Nicholas Moore
- Bordeaux PharmacoEpi, Univ. Bordeaux, Inserm CIC1401 & U1219, CHU Bordeaux, Bordeaux, France
| |
Collapse
|
15
|
Blin P, Samama CM, Sautet A, Mismetti P, Benichou J, Lignot-Maleyran S, Lamarque S, Lorrain S, Lassalle R, Droz-Perroteau C, Moore N. Bénéfice et risques des anticoagulants oraux directs comparativement aux héparines de bas poids moléculaire dans la prévention thromboembolique après une prothèse totale de hanche ; cohorte de près de 100 000 patients issus de la base nationale du Sniiram. Rev Epidemiol Sante Publique 2017. [DOI: 10.1016/j.respe.2017.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
16
|
Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study. Pharmacoepidemiol Drug Saf 2017; 26:1561-1569. [PMID: 28573786 DOI: 10.1002/pds.4228] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Revised: 04/04/2017] [Accepted: 04/17/2017] [Indexed: 01/03/2023]
Abstract
PURPOSE To investigate sunitinib in the real-life first-line treatment of metastatic renal cell carcinoma (mRCC). METHODS SANTORIN is a French observational multicentre cohort. Patients initiating sunitinib in first-line mRCC therapy were included (January 2008 to April 2010) and followed for 24 months. Data were collected from medical files. The outcomes were 24-month overall survival (OS) and progression-free survival (PFS), response and safety. RESULTS Three hundred two patients were included: median age, 64.8 years; male, 73.2%; clear cell mRCC, 83.1%; prior nephrectomy, 85.4%; >1 metastatic sites, 64.2%; brain metastases, 6.3%; ECOG-PS ≥ 2, 9.9%. Median duration of first-line therapy with sunitinib was 10.7 months. Initial sunitinib dose was 50 mg/day for 83.4% of patients; dose reduction occurred in 65.2%. Sunitinib was discontinued in 73.2% of the patients: for progression (61.1%), death (31.2%) or adverse events (6.8%). More than half (58.3%) had grade ≥3 adverse events, mainly hypertension (12.6%) and hand-foot syndrome (12.3%). The 24-month OS and PFS rates [95%CI] were 49.5% [43.7;55.0] and 16.4% [12.5;20.9], respectively. Median OS was 23.6 months [20.2;-] and median PFS 8.4 months [7.6;9.9]. Overall best response rate was 31.1%. CONCLUSIONS Results from this large observational study suggest that effectiveness of sunitinib in first-line mRCC as predicted by clinical trials is maintained in real-life clinical practice. The expected benefit in poor-prognosis patients that were not evaluated in the pivotal clinical trial remains; however, questionable and long-term safety monitoring is still warranted. Copyright © 2017 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Pernelle Noize
- Bordeaux PharmacoEpi, Inserm CIC1401, Bordeaux, France.,CHU Bordeaux, Bordeaux, France.,Bordeaux Population Health Research Centre, Pharmacoepidemiology team, Inserm U1219, Bordeaux, France
| | | | - Jacques-Olivier Bay
- CHU Clermont-Ferrand, Site Estaing et Centre Jean Perrin, Clermont-Ferrand, France
| | | | | | | | | | - Flore Moulin
- CHU Bordeaux, Bordeaux, France.,University Bordeaux, Bordeaux, France
| | | | | | | | | | | | - Magali Rouyer
- Bordeaux PharmacoEpi, Inserm CIC1401, Bordeaux, France
| | | | - Nicholas Moore
- Bordeaux PharmacoEpi, Inserm CIC1401, Bordeaux, France.,CHU Bordeaux, Bordeaux, France.,Bordeaux Population Health Research Centre, Pharmacoepidemiology team, Inserm U1219, Bordeaux, France.,University Bordeaux, Bordeaux, France
| | - Annie Fourrier-Réglat
- Bordeaux PharmacoEpi, Inserm CIC1401, Bordeaux, France.,CHU Bordeaux, Bordeaux, France.,Bordeaux Population Health Research Centre, Pharmacoepidemiology team, Inserm U1219, Bordeaux, France.,University Bordeaux, Bordeaux, France
| | - Alain Ravaud
- CHU Bordeaux, Bordeaux, France.,University Bordeaux, Bordeaux, France
| |
Collapse
|
17
|
Molimard M, Raherison C, Lignot S, Lamarque S, Balestra A, Chartier A, Droz C, Lassale R, Moore N, Girodet PO. La mauvaise utilisation des systèmes d’inhalation est associée à la survenue d’exacerbations sévères de BPCO : évaluation en vie réelle de 2935 patients. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Molimard M, Raherison C, Lamarque S, Lignot-Maleyran S, Balestra A, Chartier A, Lassalle R, Droz-Perroteau C, Girodet PO. Importance de la manipulation des systèmes d’inhalation dans la bronchopneumopathie chronique obstructive (BPCO) : une étude observationnelle de terrain en situation réelle de soins. Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2016.10.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
19
|
Droz-Perroteau C, Lignot-Maleyran S, Lamarque S, Balestra A, Girodet PO, Molimard M, Moore N. Diminution de plus 80 % des taux de participation spontanée des médecins généralistes aux études observationnelles de pharmaco-épidémiologie en France entre 2002 et 2015 : un exemple frappant dans le domaine de la pneumologie. Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2016.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
20
|
Ryczko D, Knüsel J, Crespi A, Lamarque S, Mathou A, Ijspeert AJ, Cabelguen JM. Flexibility of the axial central pattern generator network for locomotion in the salamander. J Neurophysiol 2014; 113:1921-40. [PMID: 25540227 DOI: 10.1152/jn.00894.2014] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
In tetrapods, limb and axial movements are coordinated during locomotion. It is well established that inter- and intralimb coordination show considerable variations during ongoing locomotion. Much less is known about the flexibility of the axial musculoskeletal system during locomotion and the neural mechanisms involved. Here we examined this issue in the salamander Pleurodeles waltlii, which is capable of locomotion in both aquatic and terrestrial environments. Kinematics of the trunk and electromyograms from the mid-trunk epaxial myotomes were recorded during four locomotor behaviors in freely moving animals. A similar approach was used during rhythmic struggling movements since this would give some insight into the flexibility of the axial motor system. Our results show that each of the forms of locomotion and the struggling behavior is characterized by a distinct combination of mid-trunk motor patterns and cycle durations. Using in vitro electrophysiological recordings in isolated spinal cords, we observed that the spinal networks activated with bath-applied N-methyl-d-aspartate could generate these axial motor patterns. In these isolated spinal cord preparations, the limb motor nerve activities were coordinated with each mid-trunk motor pattern. Furthermore, isolated mid-trunk spinal cords and hemicords could generate the mid-trunk motor patterns. This indicates that each side of the cord comprises a network able to generate coordinated axial motor activity. The roles of descending and sensory inputs in the behavior-related changes in axial motor coordination are discussed.
Collapse
Affiliation(s)
- D Ryczko
- Institut National de la Santé et de la Recherche Médicale (INSERM) U 862-Neurocentre Magendie, Université de Bordeaux, Bordeaux Cedex, France; and
| | - J Knüsel
- Biorobotics Laboratory (BIOROB), Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - A Crespi
- Biorobotics Laboratory (BIOROB), Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - S Lamarque
- Institut National de la Santé et de la Recherche Médicale (INSERM) U 862-Neurocentre Magendie, Université de Bordeaux, Bordeaux Cedex, France; and
| | - A Mathou
- Institut National de la Santé et de la Recherche Médicale (INSERM) U 862-Neurocentre Magendie, Université de Bordeaux, Bordeaux Cedex, France; and
| | - A J Ijspeert
- Biorobotics Laboratory (BIOROB), Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - J M Cabelguen
- Institut National de la Santé et de la Recherche Médicale (INSERM) U 862-Neurocentre Magendie, Université de Bordeaux, Bordeaux Cedex, France; and
| |
Collapse
|
21
|
Blin P, Dureau C, Lamarque S, Bernard MA, Robinson P, Lassalle R, Grolleau A, Droz C, Moore N. Misuse, Abuse, and Diversion of instanyl® (Fentanyl Nasal Spray) in France. Value Health 2014; 17:A649. [PMID: 27202339 DOI: 10.1016/j.jval.2014.08.2357] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- P Blin
- INSERM CIC Bordeaux CIC1401, Univ. Bordeaux, Bordeaux, France
| | - C Dureau
- INSERM CIC Bordeaux CIC1401, Univ. Bordeaux, Bordeaux, France
| | - S Lamarque
- INSERM CIC Bordeaux CIC1401, Univ. Bordeaux, Bordeaux, France
| | - M A Bernard
- INSERM CIC Bordeaux CIC1401, Univ. Bordeaux, Bordeaux, France
| | - P Robinson
- INSERM CIC Bordeaux CIC1401, Univ. Bordeaux, Bordeaux, France
| | - R Lassalle
- INSERM CIC Bordeaux CIC1401, Univ. Bordeaux, Bordeaux, France
| | - A Grolleau
- INSERM CIC Bordeaux CIC1401, Univ. Bordeaux, Bordeaux, France
| | - C Droz
- INSERM CIC Bordeaux CIC1401, Univ. Bordeaux, Bordeaux, France
| | - N Moore
- INSERM CIC Bordeaux CIC1401, Univ. Bordeaux, INSERM U657, CHU Bordeaux, Bordeaux, France
| |
Collapse
|
22
|
Blin P, Dureau C, Lamarque S, Bernard MA, Robinson P, Lassalle R, Grolleau A, Droz C, Moore N. Mésusage, abus et détournement d’Instanyl® (fentanyl par voie nasale) en France. Rev Epidemiol Sante Publique 2014. [DOI: 10.1016/j.respe.2014.05.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
23
|
Abstract
Much of what we know about the flexibility of the locomotor networks in vertebrates is derived from studies examining the adaptation of limb movements during stepping in various conditions. However, the body movements play important roles during locomotion: they produce the thrust during undulatory locomotion and they help to increase the stride length during legged locomotion. In this chapter, we review our current knowledge about the flexibility in the neuronal circuits controlling the body musculature during locomotion. We focus especially on salamander because, as an amphibian, this animal is able to display a rich repertoire of aquatic and terrestrial locomotor modes.
Collapse
Affiliation(s)
- Jean-Marie Cabelguen
- Neurocentre Magendie, INSERM U 862, Université de Bordeaux, Bordeaux Cedex, France
| | | | | | | |
Collapse
|
24
|
Laharie D, Droz-Perroteau C, Bénichou J, Amouretti M, Blin P, Bégaud B, Guiard E, Dutoit S, Lamarque S, Moride Y, Depont F, Fourrier-Réglat A, Moore N. Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. Br J Clin Pharmacol 2010; 69:295-302. [PMID: 20233201 DOI: 10.1111/j.1365-2125.2009.03588.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
AIMS To assess hospital admission rates for gastrointestinal (GI) or cardiovascular (CV) events in real-life use of nonsteroidal anti-inflammatory drugs (NSAIDs). METHODS CADEUS is a real-life population-based cohort study of 23 535 coxib (celecoxib or rofecoxib) and 22 919 traditional NSAID (tNSAID) users. Each hospitalization reported between index day (NSAID delivery) and questionnaire submission (median = 75 days) was explored using hospital discharge summaries. An expert committee validated blindly serious GI and CV events according to predefined criteria. RESULTS Coxib users were older and had more GI history than tNSAID users. There were 21 hospitalizations for GI events, 12 in the coxib cohort and nine in the tNSAID cohort (respectively one and three upper GI haemorrhages and no ulcer perforations). Rates of GI events were 0.39 per 1000 patients [95% confidence interval (CI) 0.18, 0.75] for tNSAID users and 0.51 per 1000 patients (95% CI 0.26, 0.89) for coxib users. There were 21 hospitalizations for CV events, 13 in the coxib cohort and eight in the tNSAID cohort. None was fatal. Rates of CV events were, respectively, 0.59 (95% CI 0.24, 1.22), 0.51 (95% CI 0.19, 1.11) and 0.35 (95% CI 0.15, 0.69) per 1000 patients for celecoxib, rofecoxib and tNSAIDs. GI or CV event rates were not different between products even for patients >60 years old. CONCLUSIONS Hospitalization rates for GI bleeding were 10-20 times lower than expected from published randomized clinical trials, probably because of differences in drug usage and concomitant gastroprotection. CV event rates conformed to those expected from general population data. These results emphasize the necessity of developing population healthcare databases to explore such low event rates.
Collapse
|
25
|
Blin P, Lignot S, Lassalle R, Lamarque S, Bernard MA, Demeaux JL, Housset B, Mayaud C, Peyramond D, Pouchain D, Moore N, Molimard M. Efficacité en situation réelle de la stratégie thérapeutique initiale dans l’exacerbation aiguë de la bronchite chronique (EABC) en France. Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.07.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
26
|
Lazarini F, Mouthon MA, Gheusi G, de Chaumont F, Olivo-Marin JC, Lamarque S, Abrous DN, Boussin FD, Lledo PM. Cellular and behavioral effects of cranial irradiation of the subventricular zone in adult mice. PLoS One 2009; 4:e7017. [PMID: 19753118 PMCID: PMC2737283 DOI: 10.1371/journal.pone.0007017] [Citation(s) in RCA: 151] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2009] [Accepted: 07/13/2009] [Indexed: 11/25/2022] Open
Abstract
Background In mammals, new neurons are added to the olfactory bulb (OB) throughout life. Most of these new neurons, granule and periglomerular cells originate from the subventricular zone (SVZ) lining the lateral ventricles and migrate via the rostral migratory stream toward the OB. Thousands of new neurons appear each day, but the function of this ongoing neurogenesis remains unclear. Methodology/Principal Findings In this study, we irradiated adult mice to impair constitutive OB neurogenesis, and explored the functional impacts of this irradiation on the sense of smell. We found that focal irradiation of the SVZ greatly decreased the rate of production of new OB neurons, leaving other brain areas intact. This effect persisted for up to seven months after exposure to 15 Gray. Despite this robust impairment, the thresholds for detecting pure odorant molecules and short-term olfactory memory were not affected by irradiation. Similarly, the ability to distinguish between odorant molecules and the odorant-guided social behavior of irradiated mice were not affected by the decrease in the number of new neurons. Only long-term olfactory memory was found to be sensitive to SVZ irradiation. Conclusion/Significance These findings suggest that the continuous production of adult-generated neurons is involved in consolidating or restituting long-lasting olfactory traces.
Collapse
Affiliation(s)
- Françoise Lazarini
- Institut Pasteur, Laboratory for Perception and Memory, Paris, France
- Centre National de la Recherche Scientifique (CNRS) Unité de Recherche Associée (URA), Paris, France
| | - Marc-André Mouthon
- CEA, DSV, iRCM, SCSR, Laboratoire de RadioPathologie, INSERM U967, Fontenay-aux-Roses, France
| | - Gilles Gheusi
- Institut Pasteur, Laboratory for Perception and Memory, Paris, France
- Centre National de la Recherche Scientifique (CNRS) Unité de Recherche Associée (URA), Paris, France
| | - Fabrice de Chaumont
- Institut Pasteur, Unité Analyse d'Images Quantitative, CNRS (URA 2582), Paris, France
| | | | - Stéphanie Lamarque
- INSERM U862, Neurocentre Magendie, Neurogenesis and Pathophysiology group, Bordeaux, France
- Université de Bordeaux, Bordeaux, France
| | - Djoher Nora Abrous
- INSERM U862, Neurocentre Magendie, Neurogenesis and Pathophysiology group, Bordeaux, France
- Université de Bordeaux, Bordeaux, France
| | - François D. Boussin
- CEA, DSV, iRCM, SCSR, Laboratoire de RadioPathologie, INSERM U967, Fontenay-aux-Roses, France
| | - Pierre-Marie Lledo
- Institut Pasteur, Laboratory for Perception and Memory, Paris, France
- Centre National de la Recherche Scientifique (CNRS) Unité de Recherche Associée (URA), Paris, France
- * E-mail:
| |
Collapse
|
27
|
Lamarque S, Lassalle R, Bernard M, Gullemot D, Demeaux J, Housset B, Mayaud C, Peyramond D, Pouchain D, Blin P, Moore N, Molimard M. Prise en charge de l’exacerbation aiguë de la bronchite chronique (EABC) en pratique courante. Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.02.128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
28
|
Dupret D, Fabre A, Döbrössy MD, Panatier A, Rodríguez JJ, Lamarque S, Lemaire V, Oliet SHR, Piazza PV, Abrous DN. Spatial learning depends on both the addition and removal of new hippocampal neurons. PLoS Biol 2008; 5:e214. [PMID: 17683201 PMCID: PMC1939885 DOI: 10.1371/journal.pbio.0050214] [Citation(s) in RCA: 289] [Impact Index Per Article: 18.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2007] [Accepted: 06/11/2007] [Indexed: 12/18/2022] Open
Abstract
The role of adult hippocampal neurogenesis in spatial learning remains a matter of debate. Here, we show that spatial learning modifies neurogenesis by inducing a cascade of events that resembles the selective stabilization process characterizing development. Learning promotes survival of relatively mature neurons, apoptosis of more immature cells, and finally, proliferation of neural precursors. These are three interrelated events mediating learning. Thus, blocking apoptosis impairs memory and inhibits learning-induced cell survival and cell proliferation. In conclusion, during learning, similar to the selective stabilization process, neuronal networks are sculpted by a tightly regulated selection and suppression of different populations of newly born neurons. The birth of adult hippocampal neurons is associated with enhanced learning and memory performance. In particular, spatial learning increases the survival and the proliferation of newborn cells, but surprisingly, it also decreases their number. Here, we hypothesized that spatial learning also depends upon the death of newborn hippocampal neurons. We examined the effect of spatial learning in the water maze on cell birth and death in the rodent hippocampus. We then determined the influence of an inhibitor of cell death on memory abilities and learning-induced changes in cell death, cell proliferation, and cell survival. We show that learning increases the elimination of the youngest newborn cells during a specific developmental period. The cell-death inhibitor impairs memory abilities and blocks the learning-induced cell death, the survival-promoting effect of learning on older newly born neurons, and the subsequent learning-induced proliferation of neural precursors. These results show that spatial learning induces cell death in the hippocampus, a phenomenon that subserves learning and is necessary for both the survival of older newly born neurons and the proliferation of neural precursors. These findings suggest that during learning, neuronal networks are sculpted by a tightly regulated selection of newly born neurons and reveal a novel mechanism mediating learning and memory in the adult brain. Spatial learning-induced cell death in the hippocampus is necessary for the survival of newly born cells, the proliferation of neural precursors, and the retention of spatial memories.
Collapse
Affiliation(s)
- David Dupret
- INSERM U862, Bordeaux Neuroscience Research Center, Bordeaux, France
- University of Bordeaux 2, Bordeaux, France
| | - Annabelle Fabre
- INSERM U862, Bordeaux Neuroscience Research Center, Bordeaux, France
- University of Bordeaux 2, Bordeaux, France
| | - Màtè Dàniel Döbrössy
- INSERM U862, Bordeaux Neuroscience Research Center, Bordeaux, France
- University of Bordeaux 2, Bordeaux, France
| | - Aude Panatier
- INSERM U862, Bordeaux Neuroscience Research Center, Bordeaux, France
- University of Bordeaux 2, Bordeaux, France
| | | | - Stéphanie Lamarque
- INSERM U862, Bordeaux Neuroscience Research Center, Bordeaux, France
- University of Bordeaux 2, Bordeaux, France
| | - Valerie Lemaire
- INSERM U862, Bordeaux Neuroscience Research Center, Bordeaux, France
- University of Bordeaux 2, Bordeaux, France
| | - Stephane H. R Oliet
- INSERM U862, Bordeaux Neuroscience Research Center, Bordeaux, France
- University of Bordeaux 2, Bordeaux, France
| | - Pier-Vincenzo Piazza
- INSERM U862, Bordeaux Neuroscience Research Center, Bordeaux, France
- University of Bordeaux 2, Bordeaux, France
| | - Djoher Nora Abrous
- INSERM U862, Bordeaux Neuroscience Research Center, Bordeaux, France
- University of Bordeaux 2, Bordeaux, France
- * To whom correspondence should be addressed. E-mail:
| |
Collapse
|
29
|
Lamarque S, Taghzouti K, Simon H. Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction. Neuropharmacology 2001; 41:118-29. [PMID: 11445192 DOI: 10.1016/s0028-3908(01)00039-9] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cannabis sativa preparations are some of the most widely used illicit recreational drugs. In addition to their direct addictive potential, cannabinoids may influence the sensitivity to other drugs. The aim of the present study was to determine if a cross-sensitization between Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and other drugs (amphetamine and heroin) could be demonstrated. We examined the effects of a chronic treatment with Delta(9)-THC (0.6, 3 and 15mg/kg, ip) on the locomotor response to amphetamine (1mg/kg, ip) and heroin (1mg/kg, ip). Chronic treatment with Delta(9)-THC resulted in tolerance to the initial hypothermic and anorexic effects. Pre-treatment with Delta(9)-THC increased the locomotor responses to amphetamine and heroin. This cross-sensitization was time-dependent as it was observed three days after the last injection of Delta(9)-THC for amphetamine, and a relatively long time after the end of chronic treatment (41 days) for heroin. Moreover, the enhanced response to amphetamine or heroin was noted in some individuals only: the high-responder rats (HR). These animals have previously been shown to be vulnerable to drug taking behaviors. It is hypothesised that repeated use of Cannabis derivates may facilitate progression to the consumption of other illicit drugs in vulnerable individuals.
Collapse
Affiliation(s)
- S Lamarque
- Laboratoire de Neuropsychobiologie des Désadaptations, Université Victor Segalen Bordeaux 2, CNRS UMR 5541, BP 31, 146, rue Léo Saignat, 33076 Bordeaux Cedex, France
| | | | | |
Collapse
|
30
|
Taghzouti K, Lamarque S, Kharouby M, Simon H. Interindividual differences in active and passive behaviors in the forced-swimming test: implications for animal models of psychopathology. Biol Psychiatry 1999; 45:750-8. [PMID: 10188005 DOI: 10.1016/s0006-3223(98)00156-5] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND In common with other animal models of psychopathology, the forced-swimming test (FST) suffers from the fact that it involves normal animals. Moreover, powerful antidepressant drugs such as the selective serotonin reuptake inhibitors have been found to give false negatives in this behavioral test. METHODS To circumvent these theoretical and practical difficulties, we studied the interindividual variability of the behavioral reactivity of rats in the FST. The effects of fluoxetine treatment or of a stressful experience (repeated testing in the FST) were analyzed on various behavioral responses. RESULTS The following observations were made in replicated experiments: 1) a dimensional behavioral response from passivity to high reactivity in the FST; 2) an antidepressant-like effect of fluoxetine only in a subgroup of animals categorized as low responders on the dimension of passivity-reactivity; and 3) a switch toward passive responses following a past experience of stress, which was corrected by fluoxetine treatment. CONCLUSIONS It is concluded that a dimensional approach could improve the screening of antidepressant drugs and could aid the development of new ones by identifying the biobehavioral characteristics of responder and nonresponder subjects.
Collapse
Affiliation(s)
- K Taghzouti
- Laboratoire de Physiologie Animale, Faculté des Sciences, Rabat, Morocco
| | | | | | | |
Collapse
|
31
|
Hamou E, Lamarque S. [Impact of facial aging on the treatment strategy in orthodontics]. Orthod Fr 1997; 68:63-74. [PMID: 9432626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|
32
|
Abstract
The treatment of a Class II, Division 1 malocclusion without the extraction of premolars is, in many situations, the best solution for the patient. Nonpremolar extraction diagnosis followed by mechanotherapy with a nontorqued, nonangulated .022 edgewise appliance and the "Twelve-Two" System of Sequential Directional Force application is described.
Collapse
|
33
|
Abstract
Control of the occlusal plane during orthodontic mechanotherapy should be an integral part of every clinician's treatment plan. The many ramifications of occlusal plane control during the treatment of normodivergent, hyperdivergent, and hypodivergent skeletal patterns are discussed. The force systems and treatment mechanics used during treatment of the three different skeletal types and the impact these systems have on occlusal plane control are explained.
Collapse
|